GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Shares Outstanding (EOP)

EV Biologics (EV Biologics) Shares Outstanding (EOP) : 2.41 Mil (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. EV Biologics's shares outstanding for the quarter that ended in Dec. 2017 was 2.41 Mil.

EV Biologics's quarterly shares outstanding stayed the same from Jun. 2017 (2.41 Mil) to Dec. 2017 (2.41 Mil).

EV Biologics's annual shares outstanding increased from Jun. 2016 (2.40 Mil) to Jun. 2017 (2.41 Mil). It means EV Biologics issued new shares from Jun. 2016 to Jun. 2017 .


EV Biologics Shares Outstanding (EOP) Historical Data

The historical data trend for EV Biologics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Shares Outstanding (EOP) Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Shares Outstanding (EOP)
2.37 2.37 1.60 2.40 2.41

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 2.41 2.41 2.41 2.41

Competitive Comparison of EV Biologics's Shares Outstanding (EOP)

For the Biotechnology subindustry, EV Biologics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where EV Biologics's Shares Outstanding (EOP) falls into.



EV Biologics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


EV Biologics  (OTCPK:YECO) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


EV Biologics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of EV Biologics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics NFT Dividend Update

By ACCESSWIRE ACCESSWIRE 07-19-2021

EV Biologics Updates on Excyte Subsidiary Funding

By ACCESSWIRE ACCESSWIRE 01-03-2023

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021

EV Biologics Briefs Shareholders on Market Cap Peer Comparison

By ACCESSWIRE ACCESSWIRE 08-12-2021

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

By ACCESSWIRE ACCESSWIRE 11-14-2022